Betty C. Pang

San Francisco
  • 505 Montgomery Street
  • Suite 2000
  • San Francisco, CA 94111-6538
  • USA
 
 

Dr. Pang represents private equity firms and investment banks, healthcare providers and health systems, and life science companies, including pharmaceutical, medical device, and biotechnology companies, and medical suppliers on regulatory issues pertaining to fraud and abuse, self-referral and government program reimbursement compliance, and facility and provider licensing issues, including:

  • Mergers and acquisitions
  • Initial public offerings
  • Financings
  • Joint ventures
  • Government investigations
  • Day-to-day regulatory counseling

Dr. Pang is a member of the American Health Lawyers Association, the California Society for Healthcare Attorneys, and the American Bar Association Health Law Section.

In connection with her transactional practice and general representation of healthcare industry clients, Dr. Pang also represents commercial lenders, private equity firms, and investment banks in healthcare transactions.

Over the last several years, Dr. Pang has advised on numerous capital markets, mergers and acquisitions, and finance transactions for the following clients:  

Capital Markets
  • Imago BioSciences in its US$134.4 million initial public offering
  • Aligos Therapeutics in its US$173 million initial public offering
  • Prothena in its US$72.6 million offering
  • Prometheus Biosciences, Inc. in its US$218 million initial public offering
  • Oscar Health, Inc. in its US$1.44 billion initial public offering
  • Rhythm Pharmaceuticals, Inc. in its US$172 million common stock offering
  • Angion Biomedical in its US$117 million initial public offering
  • Sana Biotechnology, Inc. in its US$675 initial public offering
  • Revolution Medicines, Inc. in its US$300 million common stock offering
  • Arcutis Biotherapeutics, Inc. in its US$183 million common stock offering
  • Aimmune Therapeutics in its US$160 million initial public offering
  • Ascendis Pharma in its US$500 million initial public offering and subsequent US$500 million convertible notes offering
  • Corvus Pharmaceuticals in its US$60 million follow-on offering
  • CytomX Therapeutics in its US$116.9 million initial public offering and follow-on offering
  • Gritstone Oncology in its US$74.8 million offering
  • Teladoc in its US$180 million initial public offering
  • Numerous underwriters in various offerings, including:
    • Minerva Surgical’s US$75 million initial public offering
    • Eliem Therapeutics’ initial public offering
    • Petco’s US$279 initial public offering
    • Aclaris Therapeutics, Inc.’s US$25 million at-the-market offering
    • Instil Bio, Inc.’s US$320 million initial public offering
    • Aspira Women’s Health Inc.’s US$52 million common stock offering
    • Vor Biopharma Inc.’s US$203 million initial public offering
    • Halozyme Therapeutics, Inc.’s US$700 million convertible senior notes offering
    • Sientra, Inc.’s US$42 million common stock offering
Mergers and Acquisitions
  • CooperCompanies in its acquisition of Cook Medical’s Reproductive Health business
  • Eleusis in its US$446 million business combination with Silver Spike Acquisition Corp. II
  • Preventice Solutions, Inc. in its US$1.23 billion sale to Boston Scientific
  • North American Science Associates, Inc. (NAMSA) in its US$43.5 million acquisition of American Preclinical Services, LLC
  • Pionyr Immunotherapeutics in its US$275 million sale to Gilead Sciences
  • KKR in its:
    • US$1.4 billion acquisition of PharMerica
    • US$354 million acquisition of Covenant Surgical Partners
  • Leonard Green & Partners L.P. in its US$363 million acquisition of Prospect Medical Holdings
  • Bonti in its US$195 million sale to Allergan
Finance
  • Innocoll Biotherapeutics in its US$125 million term loan provided by funds managed by Oaktree Capital
  • JPMorgan in the
    • US$3.65 billion term loan and revolving credit facility for PPD, Inc., a global contract research organization that provides drug discovery, clinical development, lifecycle management, and laboratory services, to refinance existing debt
    • US$38.3 billion term loan facilities in connection with Takeda Pharmaceutical Company Limited's acquisition of Shire plc, an Ireland-based biopharmaceutical company
  • Deutsche Bank in the incremental term loan and revolving credit facility in connection with Endo Limited's acquisition of Par Pharmaceutical Holdings, Inc., a specialty pharmaceutical company
  • Bank of America and Merrill Lynch, Fenner, Pierce & Smith in the US$3 billion term loan and revolving credit facilities in connection with Gilead Science’s US$11.2 billion acquisition of Pharmasset, Inc., a clinical stage pharmaceutical company focused primarily on developing oral therapeutics for the treatment of hepatitis C
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.